Sign in
HALO Stock Price, Chart, Stats & News
Halozyme Therapeutics Inc
Save
Halozyme Therapeutics Inc (HALO) does not currently pay a dividend.
8.90B
Market cap
16.24x
Current P/E
10.55x
Forward P/E
HALO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 81.95% |
Operating margin | 58.45% |
Pretax margin | 33.43% |
Net margin | 22.69% |
Effective tax rate | 32.13% |
ROA | 12.55% |
ROE | 92.67% |
D/E | – |
Interest coverage ratio | 45.03x |
HALO valuation
P/E | 16.24x |
P/S | 5.21x |
P/B | 148.57x |
P/CF | 11.13x |
P/FCF | 11.28x |
P/OCF | 11.13x |
PEG | -0.49x |
EV multiple | 7.68x |
About
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines.
Similar securities
Based on sector and market capitalization
Report issue